These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25148682)

  • 21. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor.
    Sawant M; Wilson A; Sridaran D; Mahajan K; O'Conor CJ; Hagemann IS; Luo J; Weimholt C; Li T; Roa JC; Pandey A; Wu X; Mahajan NP
    Oncogene; 2023 Jul; 42(29):2263-2277. PubMed ID: 37330596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.
    Zhu J; Liu Y; Zhao M; Cao K; Ma J; Peng S
    Aging (Albany NY); 2021 Jan; 13(3):4482-4502. PubMed ID: 33495411
    [No Abstract]   [Full Text] [Related]  

  • 25. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
    Ramadoss S; Guo G; Wang CY
    Oncogene; 2017 Jan; 36(1):47-59. PubMed ID: 27270439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
    Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
    Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
    Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
    Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells.
    Sakla MS; Shenouda NS; Ansell PJ; Macdonald RS; Lubahn DB
    Endocrine; 2007 Aug; 32(1):69-78. PubMed ID: 17992604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
    Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
    J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.
    Riggins RB; Thomas KS; Ta HQ; Wen J; Davis RJ; Schuh NR; Donelan SS; Owen KA; Gibson MA; Shupnik MA; Silva CM; Parsons SJ; Clarke R; Bouton AH
    Cancer Res; 2006 Jul; 66(14):7007-15. PubMed ID: 16849545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A role for the non-receptor tyrosine kinase ACK1 in TNF-alpha-mediated apoptosis and proliferation in human intestinal epithelial caco-2 cells.
    Zhao X; Lv C; Chen S; Zhi F
    Cell Biol Int; 2018 Sep; 42(9):1097-1105. PubMed ID: 28921811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.
    Yokoyama N; Miller WT
    J Biol Chem; 2003 Nov; 278(48):47713-23. PubMed ID: 14506255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
    Nakatsuka T; Tateishi K; Kudo Y; Yamamoto K; Nakagawa H; Fujiwara H; Takahashi R; Miyabayashi K; Asaoka Y; Tanaka Y; Ijichi H; Hirata Y; Otsuka M; Kato M; Sakai J; Tachibana M; Aburatani H; Shinkai Y; Koike K
    Oncogene; 2017 Nov; 36(45):6262-6271. PubMed ID: 28692045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.